(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.38%) $966.30
(-0.36%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.36%) $91.45
Live Chart Being Loaded With Signals
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures...
Stats | |
---|---|
本日の出来高 | 1.06M |
平均出来高 | 959 743 |
時価総額 | 10.80B |
EPS | $0 ( 2024-02-27 ) |
次の収益日 | ( $0 ) 2024-08-01 |
Last Dividend | $0.288 ( 2023-10-05 ) |
Next Dividend | $0 ( N/A ) |
P/E | 41.30 |
ATR14 | $0.0100 (0.04%) |
ボリューム 相関
Smith & Nephew SNATS Inc. 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Smith & Nephew SNATS Inc. 相関 - 通貨/商品
Smith & Nephew SNATS Inc. 財務諸表
Annual | 2023 |
収益: | $5.55B |
総利益: | $3.70B (66.70 %) |
EPS: | $0.600 |
FY | 2023 |
収益: | $5.55B |
総利益: | $3.70B (66.70 %) |
EPS: | $0.600 |
FY | 2022 |
収益: | $5.22B |
総利益: | $3.70B (70.85 %) |
EPS: | $0.510 |
FY | 2021 |
収益: | $5.21B |
総利益: | $3.67B (70.40 %) |
EPS: | $1.196 |
Financial Reports:
No articles found.
Smith & Nephew SNATS Inc. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.288 (N/A) |
$0 (N/A) |
$0.462 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0.288 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.139 | 2000-05-04 |
Last Dividend | $0.288 | 2023-10-05 |
Next Dividend | $0 | N/A |
Payout Date | 2023-11-01 | |
Next Payout Date | N/A | |
# dividends | 48 | -- |
Total Paid Out | $10.43 | -- |
Avg. Dividend % Per Year | 1.50% | -- |
Score | 4.34 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.49 | |
Div. Directional Score | 7.54 | -- |
Year | Amount | Yield |
---|---|---|
2000 | $0.194 | 2.88% |
2001 | $0.146 | 1.58% |
2002 | $0.154 | 1.28% |
2003 | $0.169 | 1.36% |
2004 | $0.184 | 1.10% |
2005 | $0.194 | 0.96% |
2006 | $0.204 | 1.08% |
2007 | $0.223 | 1.07% |
2008 | $0.247 | 1.07% |
2009 | $0.271 | 2.08% |
2010 | $0.299 | 1.45% |
2011 | $0.328 | 1.56% |
2012 | $0.414 | 2.12% |
2013 | $0.532 | 2.39% |
2014 | $0.560 | 1.98% |
2015 | $0.608 | 1.69% |
2016 | $0.626 | 1.80% |
2017 | $0.616 | 2.05% |
2018 | $0.734 | 2.10% |
2019 | $0.728 | 2.00% |
2020 | $0.750 | 1.55% |
2021 | $0.750 | 1.75% |
2022 | $0.750 | 2.14% |
2023 | $0.750 | 2.75% |
2024 | $0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
LOMA | Dividend Knight | 2023-06-30 | Quarterly | 2 | 5.23% | 8.53 |
PHK | Dividend Royal | 2023-11-10 | Monthly | 22 | 6.88% | 8.50 |
PCF | Dividend King | 2023-12-18 | Monthly | 38 | 7.05% | 8.50 |
ZTR | Dividend King | 2024-02-09 | Monthly | 37 | 8.35% | 8.50 |
PVL | Dividend King | 2023-11-15 | Monthly | 14 | 9.37% | 8.50 |
KIO | Dividend Royal | 2023-12-14 | Monthly | 12 | 7.05% | 8.50 |
NCV | Dividend Royal | 2024-02-09 | Monthly | 22 | 7.68% | 8.50 |
SBR | Dividend Royal | 2023-11-14 | Monthly | 38 | 7.74% | 8.50 |
SCM | Dividend King | 2023-12-15 | Monthly | 13 | 7.08% | 8.50 |
MTR | Dividend Diamond | 2023-10-30 | Monthly | 39 | 10.10% | 8.50 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0475 | 1.500 | 9.05 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0263 | 1.200 | 9.12 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0502 | 1.500 | -0.553 | -0.830 | [0.1 - 1] |
payoutRatioTTM | 1.247 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 1.775 | 0.800 | 6.13 | 4.90 | [1 - 3] |
quickRatioTTM | 0.679 | 0.800 | -0.709 | -0.567 | [0.8 - 2.5] |
cashRatioTTM | 0.133 | 1.500 | -0.372 | -0.558 | [0.2 - 2] |
debtRatioTTM | 0.294 | -1.500 | 5.09 | -7.64 | [0 - 0.6] |
interestCoverageTTM | 5.49 | 1.000 | 9.08 | 9.08 | [3 - 30] |
operatingCashFlowPerShareTTM | 1.384 | 2.00 | 9.54 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.412 | 2.00 | 9.79 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.564 | -1.500 | 7.75 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.688 | 1.000 | 1.862 | 1.862 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.137 | 1.000 | 9.25 | 9.25 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.205 | 1.000 | 9.97 | 9.97 | [0.2 - 2] |
assetTurnoverTTM | 0.553 | 0.800 | 9.64 | 7.72 | [0.5 - 2] |
Total Score | 10.60 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 40.62 | 1.000 | 6.00 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0502 | 2.50 | -0.356 | -0.830 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.412 | 2.00 | 9.86 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.07 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 1.384 | 2.00 | 9.54 | 10.00 | [0 - 30] |
payoutRatioTTM | 1.247 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | -1.590 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.109 | 1.000 | 9.77 | 0 | [0.1 - 0.5] |
Total Score | 4.49 |
Smith & Nephew SNATS Inc.
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。